Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mesoblast initiates Phase I/II bone marrow transplant trial
This follows clearance by the FDA of an investigational new drug submission, and ethics approval by the Institutional Review Board at the University of Texas MD Anderson Cancer
This follows clearance by the FDA of an investigational new drug submission, and ethics approval by the Institutional Review Board at the University of Texas MD Anderson Cancer
Genedata Screener, an open and scalable enterprise solution for high throughput screening and high content screening (HTS), will be completely integrated into the center’s HTS workflows. The Drug
Although the company will maintain all of its current personnel under consulting agreements, the company’s staff will be reduced by four employees. This plan is designed to ensure
Ambulatory pumps covered under the agreement include the entire Curlin PainSmart IOD pain management system, which B Braun markets exclusively. The Curlin System is an advanced ambulatory electronic
This Phase II trial was a randomized, double-blind, placebo-controlled, multiple dose study that evaluated the efficacy and safety of three months of weekly injections of PC-DAC:Exendin-4 in patients
The company said that it now occupies 44,082sqft of space on the 12th floor of Westchester One. Ultimately, the move is slated to bring 200 new jobs to
The agreement enables Assay Designs to distribute approximately 3,200 of Abnova’s highly characterized monoclonal antibodies to its US and Canadian customers. This product addition expands Assay Designs’s current
The seven new products to be introduced will include OIS EMR, OIS PM, Symphony Web, Symphony Draw, Symphony Link, PerfectView and FAF Super-Resolution. The company said that OIS
The dossier includes Generex Oral-lyn, the company’s proprietary oral insulin spray product that reportedly provides a safe, effective and pain-free alternative to subcutaneous injections of prandial insulin for
Sancuso was previously approved by the FDA as the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients